The U.S. Food and Drug Administration approved a once-daily oral drug on Wednesday for patients with advanced or metastatic pancreatic cancer [1, 2].
The approval provides a critical treatment alternative for patients whose cancer has progressed after chemotherapy. Because pancreatic cancer is often diagnosed in late stages, new targeted therapies are essential for extending life in a disease with historically low survival rates [3, 4].
The medication, referred to as daraxonrasib or Rasonque [1, 3], targets the RAS protein. This specific protein drives approximately 95% of pancreatic adenocarcinoma cases [3]. By inhibiting this protein, the drug aims to stop the growth of tumors that have spread to other parts of the body [4].
Clinical data indicates the drug has a significant impact on patient longevity. "Patients see survival nearly double," an FDA spokesperson said [2]. The drug is administered as a pill taken once daily [2].
Some patients have reported severe side effects during treatment. Former U.S. Sen. Ben Sasse (R-NE) described his experience with the medication. "It left my skin bloody and 'bubbling,' but it's giving me hope," Sasse said [5].
Other patients have expressed similar optimism despite the challenges of the disease. A Philadelphia police officer receiving the treatment said, "It gives me hope" [1].
The FDA's decision marks a shift toward precision medicine for pancreatic cancer, moving away from broad chemotherapy toward treatments that target the genetic drivers of the tumor [4].
“"Patients see survival nearly double," the FDA spokesperson said.”
This approval represents a major step in targeted oncology by addressing the RAS protein, a biological driver that was long considered 'undruggable.' By providing a non-chemotherapy oral option, the FDA is expanding the standard of care for a patient population that typically has very few options once first-line treatments fail.
